Executive summary

This systematic review and meta-analysis conducted by the Tsukuba group, Japan, included 37 studies (photon 23, proton 14) and reported no significant differences between treatment modalities for pediatric non-parameningial rhabdomyosarcoma (RMS) in OS from 1 to 5 years. However, inferior LC rates at 1- and 3-year with PBT were reported in parameningial RMS. The authors remarked that the inferior LC rates with proton may be attributed to the limited number of proton studies.

Top cancer treatments